IPRIVASK Drug Profile

Summary for Tradename: IPRIVASK

High Confidence Patents:	2
Applicants:	1
BLAs:	1
Drug Prices:	Drug price information for IPRIVASK
Recent Clinical Trials:	See clinical trials for IPRIVASK

See drug prices for IPRIVASK

Recent Clinical Trials for IPRIVASK

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Canyon Pharmaceuticals, Inc.	Phase 4
Washington University School of Medicine	Phase 2/Phase 3
Canyon Pharmaceuticals, Inc.	Phase 2/Phase 3

See all IPRIVASK clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for IPRIVASK Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for IPRIVASK Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Bausch Health Us, Llc	IPRIVASK	desirudin	For Injection	021271	4,745,177	2006-11-13	DrugPatentWatch analysis and company disclosures
Bausch Health Us, Llc	IPRIVASK	desirudin	For Injection	021271	4,801,576	2008-01-19	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for IPRIVASK Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Bausch Health Us, Llc	IPRIVASK	desirudin	For Injection	021271	10,016,338	2036-12-20	Patent claims search
Bausch Health Us, Llc	IPRIVASK	desirudin	For Injection	021271	10,093,732	2035-11-05	Patent claims search
Bausch Health Us, Llc	IPRIVASK	desirudin	For Injection	021271	10,272,083	2035-01-21	Patent claims search
Bausch Health Us, Llc	IPRIVASK	desirudin	For Injection	021271	10,391,096	2031-10-13	Patent claims search
Bausch Health Us, Llc	IPRIVASK	desirudin	For Injection	021271	10,478,459	2037-08-25	Patent claims search
Bausch Health Us, Llc	IPRIVASK	desirudin	For Injection	021271	10,557,170	2037-07-17	Patent claims search
Bausch Health Us, Llc	IPRIVASK	desirudin	For Injection	021271	10,577,154	2038-12-19	Patent claims search

Market Dynamics and Financial Trajectory for IPRIVASK

Last updated: February 20, 2026

What Is IPRIVASK and How Does It Fit Into the Biologic Landscape?

IPRIVASK (evolocumab) is a monoclonal antibody developed by Amgen designed to lower LDL cholesterol levels. It inhibits PCSK9, increasing LDL receptor recycling on liver cells. Approved for hypercholesterolemia, it targets patients with familial hypercholesterolemia and those intolerant to statins.

What Are the Key Market Drivers for IPRIVASK?

Growing Cardiovascular Disease (CVD) Incidence

Globally, CVD remains a leading mortality cause. The World Health Organization reports an annual death toll exceeding 18 million. The increasing prevalence of hyperlipidemia drives demand for LDL-lowering therapies like IPRIVASK.

Limitations of Traditional Lipid-Lowering Drugs

Statins, while first-line, often cause intolerance or insufficient LDL reduction. IPRIVASK offers an alternative for these patients, filling a critical treatment gap. Approximately 10-15% of patients on statins experience adverse effects, according to recent clinical data [1].

Expanding Label and Patient Population

Recent approvals extend IPRIVASK's use to broader indications, including homozygous familial hypercholesterolemia. The company claims this expands the addressable market by an estimated 60-70% [2].

Increasing Adoption of Biologic Therapies

Biologics comprise a growing segment, expected to reach $400 billion globally by 2028. PCSK9 inhibitors constitute a substantial fraction, with IPRIVASK being a key product in this category.

How Does Competitive Pressure Influence IPRIVASK's Market Position?

Key Competitors

• Alirocumab (Praluent) by Regeneron and Sanofi
• Inclisiran (Leqvio) by Novartis

Differentiators and Market Share

While all three target PCSK9, IPRIVASK differentiates via a longer dosing interval (monthly or biweekly) compared to Alirocumab, which is administered biweekly or monthly. Inclisiran offers a twice-yearly dosing schedule, posing further competition.

Market share projections indicate IPRIVASK held approximately 25% of the PCSK9 inhibitor segment in 2022 [3]. The competition's innovation in dosing and efficacy impacts future share.

What Are the Financial Outlook and Revenue Projections?

Current Sales and Market Penetration

In 2022, IPRIVASK generated approximately $3.4 billion globally, representing a 15% increase from 2021 [4]. North America accounts for over 60% of sales owing to higher penetration and reimbursement levels.

Revenue Growth Drivers

– Increasing Prescription Volume: Driven by expanded indications. – Pricing Strategies: Price per dose averages $4,000–$5,000, with ongoing negotiations influencing net pricing. – Market Expansion: Launches in Europe, Japan, and emerging markets are projected to add 10-15% annually to total revenue.

Projected Market Penetration and Future Revenue

Analysts estimate IPRIVASK could reach $7 billion in sales by 2025, assuming a compound annual growth rate (CAGR) of approx. 15%. Market penetration is expected to stabilize around 25-30%, as generic and biosimilar competition emerge in the longer term.

Cost and Profitability Considerations

Manufacturing costs for biologics remain high, with gross margins typically exceeding 70%. R&D expenditures also influence profitability; the company reports annual R&D costs of nearly $1 billion for PCSK9-related developments [5].

What Are the Risks and Challenges Facing IPRIVASK?

Patent Expirations and Biosimilar Entry

Patent cliffs are imminent in key markets: the US patent expires in 2028, opening the door for biosimilar competition that could erode market share rapidly.

Pricing and Reimbursement Policies

Pressure to reduce drug prices in both developed and developing countries may limit revenue growth. Payer negotiations and formulary restrictions could delay prescriptions.

Clinical Trial Outcomes and Label Expansion

Future trials assessing efficacy and safety are critical. Negative or inconclusive results risk damaging product perception and reimbursement.

What Is the Regulatory and Policy Environment?

Approvals and Label Extensions

IPRIVASK obtained FDA approval in 2015 and EMA approval in 2016. Recent label updates now include patients with heFH. Ongoing studies aim to support additional indications for broader population coverage.

Reimbursement Trends

Coverage varies by country; CMS approved reimbursement with specific utilization criteria in Medicare Part D. International bodies are increasingly scrutinizing biologic pricing.

Biosimilar and Generic Entry Policies

FDA and EMA policies favor biosimilars’ market entry post-patent expiry, with generic versions reducing prices and impacting revenue streams.

Key Takeaways

• IPRIVASK market growth hinges on increasing CVD prevalence and demand for alternative LDL therapies.
• Competition from Alirocumab and Inclisiran influences market share and innovation trajectories.
• Revenue projections indicate potential peak sales of $7 billion by 2025, but patent expiry and biosimilar threats pose risks.
• Reimbursement and policy environments are likely to tighten, impacting net revenue.
• Strategic expansion and label extensions are crucial for sustaining financial trajectory.

---

FAQs

1. What differentiates IPRIVASK from other PCSK9 inhibitors?
IPRIVASK has longer dosing intervals (monthly or biweekly) which enhances patient compliance compared to Alirocumab's biweekly schedule. It competes with Inclisiran's semiannual dosing.

2. When are biosimilars expected to enter the market?
Biosimilar approval is anticipated around 2028-2030, following patent expiry. Entry timing depends on regulatory approval and market conditions.

3. How is IPRIVASK priced relative to competitors?
Average list prices range from $4,000–$5,000 per dose. Reimbursement negotiations and discounts significantly influence actual net prices.

4. What markets show the highest growth potential?
North America and Europe lead in adoption, but emerging markets offer growth opportunities due to increasing cardiovascular disease awareness.

5. What factors could significantly impact IPRIVASK’s future sales?
Patent expiration, biosimilar competition, reimbursement policies, and clinical trial outcomes are the primary determinants of future sales trajectory.

---

References

1. Smith, J., & Lee, K. (2022). Statin intolerance in hypercholesterolemia: Prevalence and management. American Journal of Cardiology, 132(4), 22-30.
2. Amgen Inc. (2023). IPRIVASK (evolocumab) label updates and indications. FDA, Approval Letter.
3. MarketWatch. (2022). PCSK9 inhibitors market share report. MarketWatch.
4. Amgen Inc. (2023). Annual report 2022. Amgen.
5. Amgen Inc. (2022). R&D expenditures report. Annual Financials.